Download PDF
Semin Vasc Med 2005; 5(2): 172-182
DOI: 10.1055/s-2005-872402
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA.

Homocysteine and Endothelial Function in Human Studies

Stuart J. Moat1 , Ian F. W. McDowell1
  • 1Department of Medical Biochemistry and Immunology, Wales College of Medicine, Cardiff University and the University Hospital of Wales, Cardiff, United Kingdom
Further Information

Publication History

Publication Date:
27 July 2005 (online)

    Permissions and Reprints

ABSTRACT

The endothelium plays a key role in the pathophysiology of vascular disease. Impaired flow-mediated dilatation (FMD) is a measure of endothelial dysfunction resulting from reduced bioavailability of nitric oxide (NO). Patients with homocystinuria manifest with impaired FMD, but in mild hyperhomocysteinemia, the evidence is conflicting. Oral loading with methionine or homocysteine impairs FMD, but it remains unproven that this effect is mediated directly by homocysteine. In addition, there is no clear consensus as to a mechanisms by which homocysteine would induce endothelial dysfunction. Folate administration lowers plasma homocysteine and enhances FMD. However, the effect of folate only appears to occur at high doses and with a time course that would indicate that it is acting by a mechanism independent of homocysteine lowering. It is possible that folate, in pharmacological doses, may enhance the NO activity by influencing NO-tetrahydrobiopterin interactions. These studies provide some insights and raise intriguing questions concerning the relationship between homocysteine, folate, and endothelial function. However, changes in FMD may not translate into vascular endpoints, and the outcomes of clinical intervention trials with different doses of folic acid are awaited with interest.

KEYWORDS

Endothelium - flow-mediated dilation - nitric oxide - tetrahydrobiopterin

REFERENCES

  • 1 Busse R, Fleming I. Endothelial dysfunction in atherosclerosis.  J Vasc Res. 1996;  33 181-194
    CrossrefPubMedGoogle Scholar
  • 2 Drexler H, Hornig B. Endothelial dysfunction in human disease.  J Mol Cell Cardiol. 1999;  31 51-60
    CrossrefPubMedGoogle Scholar
  • 3 Corretti M C, Anderson T J, Benjamin E J et al.. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.  J Am Coll Cardiol. 2002;  39 257-265
    PubMedGoogle Scholar
  • 4 Schachinger V, Britten M B, Zeiher A M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.  Circulation. 2000;  101 1899-1906
    CrossrefPubMedGoogle Scholar
  • 5 Suwaidi J A, Hamasaki S, Higano S T, Nishimura R A, Holmes Jr D R, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.  Circulation. 2000;  101 948-954
    CrossrefPubMedGoogle Scholar
  • 6 Gokce N, Keaney Jr J F, Hunter L M. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease.  J Am Coll Cardiol. 2003;  41 1769-1775
    CrossrefPubMedGoogle Scholar
  • 7 Halcox J P, Schenke W H, Zalos G. Prognostic value of coronary vascular endothelial dysfunction.  Circulation. 2002;  106 653-658
    CrossrefPubMedGoogle Scholar
  • 8 Esper R J, Machado R, Vilarino J et al.. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.  Am Heart J. 2000;  140 684-689
    CrossrefPubMedGoogle Scholar
  • 9 Finta K M, Fischer M J, Lee L, Gordon D, Pitt B, Webb R C. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet.  Atherosclerosis. 1993;  100 149-156
    CrossrefPubMedGoogle Scholar
  • 10 Farquharson C A, Struthers A D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.  Circulation. 2000;  101 594-597
    CrossrefPubMedGoogle Scholar
  • 11 Goodfellow J, Bellamy M F, Ramsey M W, Jones C J, Lewis M J. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia.  J Am Coll Cardiol. 2000;  35 265-270
    CrossrefPubMedGoogle Scholar
  • 12 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
    PubMedGoogle Scholar
  • 13 Effect of ramipril on martality and morvidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators.  Lancet. 1993;  342 821-828
    PubMedGoogle Scholar
  • 14 Pitt B, Zannad F, Remme W J et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.  N Engl J Med. 1999;  341 709-717
    Google Scholar
  • 15 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico.  Lancet. 1999;  354 447-455
    CrossrefPubMedGoogle Scholar
  • 16 McCully K S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.  Am J Pathol. 1969;  56 111-128
    Google Scholar
  • 17 Celermajer D S, Sorensen K, Ryalls M et al.. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents.  J Am Coll Cardiol. 1993;  22 854-858
    CrossrefPubMedGoogle Scholar
  • 18 Pullin C H, Bonham J R, McDowell I F et al.. Vitamin C therapy ameliorates vascular endothelial dysfunction in treated patients with homocystinuria.  J Inherit Metab Dis. 2002;  25 107-118
    CrossrefPubMedGoogle Scholar
  • 19 Yap S, Boers G H, Wilcken B et al.. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study.  Arterioscler Thromb Vasc Biol. 2001;  21 2080-2085
    CrossrefPubMedGoogle Scholar
  • 20 Tawakol A, Omland T, Gerhard M, Wu J T, Creager M A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.  Circulation. 1997;  95 1119-1121
    PubMedGoogle Scholar
  • 21 Woo K S, Chook P, Lolin Y I et al.. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.  Circulation. 1997;  6 2542-2544
    PubMedGoogle Scholar
  • 22 Bellamy M F. Homocysteine and endothelial function. MD thesis, University of London; 2000
    Google Scholar
  • 23 Woodman R J, Celermajer D E, Thompson P L, Hung J. Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects.  Clin Sci. 2004;  106 353-358
    PubMedGoogle Scholar
  • 24 Klerk M, Verhoef P, Clarke R, Blom H J, Kok F J, Schouten E G. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis.  JAMA. 2002;  288 2023-2031
    CrossrefPubMedGoogle Scholar
  • 25 Pullin C H, Ashfield-Watt P A, Burr M L et al.. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype.  J Am Coll Cardiol. 2001;  38 1799-1805
    CrossrefPubMedGoogle Scholar
  • 26 Butler R, Morris A D, Struthers A D. The T allele of the C(677)T 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism may protect endothelial function in young, normal subjects.  Arterioscler Thromb Vasc Biol. 2002;  22 193-194
    PubMedGoogle Scholar
  • 27 Bellamy M F, McDowell I F, Ramsey M W et al.. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults.  Circulation. 1998;  98 1848-1852
    PubMedGoogle Scholar
  • 28 Chambers J C, McGregor A, Jean-Marie J, Obeid O A, Kooner J S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy.  Circulation. 1999;  99 1156-1160
    PubMedGoogle Scholar
  • 29 Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid.  Clin Sci. 1999;  96 235-239
    PubMedGoogle Scholar
  • 30 Kanani P M, Sinkey C A, Browning R L, Allaman M, Knapp H R, Haynes W G. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans.  Circulation. 1999;  100 1161-1168
    PubMedGoogle Scholar
  • 31 Chao C L, Kuo T L, Lee Y T. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults.  Circulation. 2000;  101 485-490
    PubMedGoogle Scholar
  • 32 Nappo F, De Rosa N, Marfella R et al.. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins.  JAMA. 1999;  281 2113-2118
    CrossrefPubMedGoogle Scholar
  • 33 Hanratty C G, McAuley D F, McGurk C, Young I S, Johnston G D. Homocysteine and endothelial vascular function.  Lancet. 1998;  351 1288-1289
    PubMedGoogle Scholar
  • 34 Chambers J C, Ueland P M, Wright M, Dore C J, Refsum H, Kooner J S. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects.  Circ Res. 2001;  89 187-192
    PubMedGoogle Scholar
  • 35 Boger R H, Lentz S R, Bode-Boger S M, Knapp H R, Haynes W G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.  Clin Sci. 2001;  100 161-167
    CrossrefPubMedGoogle Scholar
  • 36 Stuhlinger M C, Oka R K, Graf E E et al.. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.  Circulation. 2003;  108 933-938
    CrossrefPubMedGoogle Scholar
  • 37 Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading.  Scand J Clin Lab Invest. 2003;  63 347-353
    PubMedGoogle Scholar
  • 38 Doshi S N, McDowell I F, Goodfellow J et al.. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine and endothelial function in healthy human subjects during experimental hyper and hypo-homocysteinaemia.  Metabolism. 2005;  54 351-360
    CrossrefPubMedGoogle Scholar
  • 39 Hanratty C, McGrath L, McAuley D, Young I, Johnston D. The effect on endothelial function of vitamin C during methionine induced hyperhomocysteinaemia.  BMC Cardiovasc Disord. 2001;  1 1 , Epub
    CrossrefPubMedGoogle Scholar
  • 40 Chao C L, Chien K L, Lee Y T. Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia.  Am J Cardiol. 1999;  84 1359-1361
    CrossrefPubMedGoogle Scholar
  • 41 Zheng H, Dimayuga C, Hudailhed A, Katz S. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects.  Aterioscler Thromb Vasc Biol. 2002;  22 E15-E18
    PubMedGoogle Scholar
  • 42 Moat S J, Lang D, McDowell I FW et al.. Folate, endothelial function and cardiovascular disease. Invited review.  J Nutr Biochem. 2004;  15 64-79
    PubMedGoogle Scholar
  • 43 Bellamy M F, McDowell I F, Ramsey M W, Brownlee M, Newcombe R G, Lewis M J. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects.  Eur J Clin Invest. 1999;  29 659-662
    CrossrefPubMedGoogle Scholar
  • 44 Woo K S, Chook P, Lolin Y I, Sanderson J E, Metreweli C, Celermajer D S. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia.  J Am Coll Cardiol. 1999;  34 2002-2006
    CrossrefPubMedGoogle Scholar
  • 45 Gori T, Burstein J M, Ahmed S et al.. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.  Circulation. 2001;  104 1119-1123
    CrossrefPubMedGoogle Scholar
  • 46 Wilmink H W, Stroes E S, Erkelens W D et al.. Influence of folic acid on postprandial endothelial dysfunction.  Arterioscler Thromb Vasc Biol. 2000;  20 185-188
    PubMedGoogle Scholar
  • 47 van Guldener C, Janssen M J, Lambert J et al.. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.  Nephrol Dial Transplant. 1998;  13 106-112
    PubMedGoogle Scholar
  • 48 Thambyrajah J, Landray M J, McGlynn F J, Jones H J, Wheeler D C, Townend J N. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?.  Circulation. 2000;  102 871-875
    PubMedGoogle Scholar
  • 49 Doshi S N, McDowell I F, Moat S J et al.. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?.  Arterioscler Thromb Vasc Biol. 2001;  21 1196-1202
    PubMedGoogle Scholar
  • 50 Doshi S N, McDowell I F, Moat S J et al.. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering.  Circulation. 2002;  105 22-26
    CrossrefPubMedGoogle Scholar
  • 51 Title L M, Cummings P M, Giddens K, Genest Jr J J, Nassar B A. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease.  J Am Coll Cardiol. 2000;  36 758-765
    CrossrefPubMedGoogle Scholar
  • 52 Chambers J C, Ueland P M, Obeid O A, Wrigley J, Refsum H, Kooner J S. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine.  Circulation. 2000;  102 2479-2483
    PubMedGoogle Scholar
  • 53 Madhavan A, Moat S J, McDowell I FW, Lewis M J, Goodfellow J, Lang D. High- but not low-dose folic acid improves endothelial function in coronary artery disease.  J Am Coll Cardiol. 2004;  43(517A) 159-1186
    PubMedGoogle Scholar
  • 54 Verhaar M C, Wever R M, Kastelein J J, van Dam T, Koomans H A, Rabelink T J. 5-methyltetrahydrofolate, the active form of folic acid restores endothelial dysfunction in familial hypercholesterolaemia.  Circulation. 1998;  97 237-241
    PubMedGoogle Scholar
  • 55 Nakano E, Higgins J A. Powers HJ. Folate protects against oxidative modification of human LDL.  Br J Nutr. 2001;  86 637-639
    PubMedGoogle Scholar
  • 56 Vasquez-Vivar J, Martasek P, Whitsett J, Joseph J, Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study.  Biochem J. 2002;  362 733-739
    CrossrefPubMedGoogle Scholar
  • 57 Stroes E, Kastelein J, Cosentino F et al.. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.  J Clin Invest. 1997;  99 41-46
    CrossrefPubMedGoogle Scholar
  • 58 Maier W, Cosentino F, Lutolf R B et al.. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease.  J Cardiovasc Pharmacol. 2000;  35 173-178
    CrossrefPubMedGoogle Scholar
  • 59 Stroes E S, van Faassen E E, Yo M et al.. Folic acid reverts dysfunction of endothelial nitric oxide synthase.  Circ Res. 2000;  86 1129-1134
    CrossrefPubMedGoogle Scholar
  • 60 Hyndman M E, Verma S, Rosenfeld R J, Anderson T J, Parsons H G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function.  Am J Physiol Heart Circ Physiol. 2002;  282 H2167-H2172
    PubMedGoogle Scholar
  • 61 Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner E. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin.  J Biol Chem. 2001;  276 40-47
    CrossrefPubMedGoogle Scholar
  • 62 Baker F, Picton D, Blackwood S et al.. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial.  Circulation. 2002;  106(Supplement 1) 741
    PubMedGoogle Scholar
  • 63 Liem A, Reynierse-Buitenwerf G H, Zwinderman A H, Juema J W, van Veldhuisen D J. Secondary prevention with folic acid: effects on clinical outcomes.  J Am Coll Cardiol. 2003;  41 2105-2113
    CrossrefPubMedGoogle Scholar
  • 64 Toole J, Malinow M R, Chambless L E et al.. Lowering homocysteine in patients with ischaemic stroke to prevent recurrent stroke, myocardial infarction, and death. The vitamin Intervention for Stroke Prevention (VISP) Randomised Controlled Study.  JAMA. 2004;  291 565-575
    CrossrefPubMedGoogle Scholar
  • 65 Lowering blood homcysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration.  BMJ. 1998;  316 894-898
    PubMedGoogle Scholar
  • 66 Doshi S N, Moat S J, McDowell I FW, Lewis M J, Goodfellow J. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?.  Atherosclerosis. 2002;  165 1-3
    CrossrefPubMedGoogle Scholar

Stuart J MoatPh.D. 

Department of Medical Biochemistry and Immunology, Wales College of Medicine, Cardiff University and the University Hospital of Wales

Heath Park, Cardiff, UK, CF14 4XW

      >